로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > Cell > PSMA > CHEK-ATP185

HEK293/Human PSMA Stable Cell Line

  1. Genetically modified cell lines best reflect MOA (Mechanism of Action)
  2. Higher activity and larger assay window for robust and reproducible cell-based bioassay
  3. Comprehensive application data to support assay development and validation
  4. Full tracible record, stringent quality control and validated cell passage stability
  5. Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
  6. Global commercial license assistance whenever regulatory filing is required
  • Description
    The HEK293/Human PSMA Stable Cell Line was engineered to express the receptor full length human PSMA (Gene ID: 2346), used to mimic cancer target cells. Surface expression of human PSMA was confirmed by flow cytometry.
  • Application

    •        Useful for cell-based PSMA binding assay

  • Growth Properties
    Adherent
  • Selection Marker
    Puromycin (2 μg/mL)
  • Culture Medium
    DMEM + 10% FBS
  • Freeze Medium
    Serum-free cell cryopreservation medium
  • Quantity
    1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
  • Storage
    Frozen in liquid nitrogen.
  • Mycoplasma Testing
    Negative
  • Sterility Testing
    Negative
  • Instructions for Use
    See data sheet for detailed culturing and assay protocol.
Receptor Assay
 PSMA FACS

Expression analysis of human PSMA on HEK293/Human PSMA Stable Cell Line by FACS.
Cell surface staining was performed on HEK293/Human PSMA Stable Cell Line or negative control cell using PE anti-human PSMA antibody after fixation with 4% paraformaldehyde.

Passage Stability
 PSMA PASSAGE

Passage stability analysis of receptors expression by FACS.
Flow cytometry surface staining of human PSMA on HEK293/Human PSMA Stable Cell Line demonstrates consistent mean fluorescent intensity across passage 4-21.

Please contact us if you are interested in related cell pool service.

  • Background
    Prostate-specific membrane antigen (PSMA) is also known as Folate hydrolase 1 (FOLH1), Glutamate carboxypeptidase 2 (GCP2), N-acetylated-alpha-linked acidic dipeptidase I (NAALAD1), which belongs to the peptidase M28 family and M28B subfamily. FOLH1 / PSMA is stable at pH greater than 6.5. FOLH1 / PSMA is a type II transmembrane zinc metallopeptidase that is most highly expressed in the nervous system, prostate, kidney, and small intestine. FOLH1 / GCP-2 is homodimer and binds 2 zinc ions per subunit, and required for NAALADase activity. The catalytic activity of PSMA involved in releasing of an unsubstituted, C-terminal glutamyl residue, typically from Ac-Asp-Glu or folylpoly – gamma - glutamates. FOLH1 / GCP-2 / PSMA has both folate hydrolase and N – acetylated – alpha – linked - acidic dipeptidase (NAALADase) activity and has a preference for tri-alpha-glutamate peptides. GCP-2 / PSMA involved in prostate tumor progression and also exhibits a dipeptidyl-peptidase IV type activity. In vitro, cleaves Gly-Pro-AMC.
  • Limited Use&License Disclosure
    1. This cell line is provided for research use only. It is neither intended for any animal or human therapeutic use nor for any direct human in vivo use. You are restricted to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
    2. ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
    3. ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
    4. Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order@acrobiosystems.com for further details.
  • Clinical and Translational Updates

코멘트 (0)


재고상품 출발날짜: 영업일 기준 4일

가격(KRW) : 5,250,000

보급 및 전시



약물 개발 현황

  • Number of Launched Drugs:5 Details
  • Number of Drugs in Clinical Trials:72 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

관련 제품

신제품

문의와 컨텐츠

This web search service is supported by Google Inc.

totop